AbbVie and ADARx Partner to Advance Next-Generation siRNA Therapies Across Neuroscience, Immunology, and Oncology in Multibillion-Dollar Collaboration AbbVie, a global biopharmaceutical leader known for its portfolio of therapies in immunology, oncology, neuroscience, and other specialty areas, has announced a significant…
AbbVie Gains First Solid Tumor FDA Approval With EMRELIS™ for High c-Met Overexpressing Advanced NSCLC AbbVie has achieved a key milestone in its oncology pipeline with the announcement that the U.S. Food and Drug Administration (FDA) has granted accelerated approval…
Novo Nordisk and Septerna Forge $2.2 Billion Global Alliance to Develop Oral Small Molecule Therapies for Obesity and Cardiometabolic Diseases In a significant expansion of its research and development pipeline, Novo Nordisk has entered into a landmark global collaboration and…
Legend Biotech Reports Strong First Quarter 2025 Performance and Strategic Milestones as CARVYKTI® Continues to Lead in Multiple Myeloma Legend Biotech Corporation, a global frontrunner in the field of cell therapy, has reported its financial results for the first quarter…
CMS Prepares Third Cycle of Drug Price Negotiations Under IRA as Trump Administration Revives Push to Lower U.S. Prescription Costs In a move that signals the growing momentum of federal efforts to control prescription drug costs, the U.S. Centers for…
AstraZeneca Unveils Expansive Respiratory Portfolio and Pioneering Clinical Data at ATS 2025 to Advance Care Across Asthma, COPD, and Inflammatory Lung Diseases AstraZeneca is poised to make a significant impact at the 2025 American Thoracic Society (ATS) International Conference in…
Merck to Unveil Broad Range of Clinical Advances Across 25+ Cancer Types at ASCO 2025 Merck (NYSE: MRK), known as MSD outside the United States and Canada, is set to make a major impact at the upcoming 2025 American Society…
Eli Lilly and Purdue University Announce Landmark $250 Million Research Collaboration Eli Lilly and Company (NYSE: LLY) and Purdue University today unveiled a major expansion of their long-standing partnership, with Lilly committing up to $250 million over the next eight…
A global healthcare company today announced positive top-line results from its Phase 3 clinical trial (NCT05139121) evaluating the contraceptive efficacy and safety of XULANE LO, an investigational low-dose weekly transdermal patch delivering 150 mcg norelgestromin and 17.5 mcg ethinyl estradiol…
AstraZeneca announced promising top-line results from its Phase III POTOMAC trial, showing that one year of treatment with Imfinzi (durvalumab) combined with standard-of-care Bacillus Calmette-Guérin (BCG) induction and maintenance therapy significantly improved disease-free survival (DFS) for patients with high-risk non-muscle-invasive…
GSK Reports Positive Phase III Results for Linerixibat in Treating Itch Associated with PBC GSK plc (LSE/NYSE: GSK) today announced positive results from its GLISTEN phase III trial evaluating linerixibat, an investigational ileal bile acid transporter (IBAT) inhibitor, in adults…
Merck Animal Health and State of Kansas Announce $895 Million Investment in De Soto Manufacturing and R&D Facilities Merck Animal Health launches its largest economic development project to date Rahway, NJ, May 8, 2025 — Merck Animal Health, known as…